Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences has disclosed an update on a previously announced plan by chairman and controlling shareholder Xiong Jun to increase his holdings in both A shares and H shares. Xiong plans to invest at least RMB100 million in total, with a minimum of RMB50 million earmarked for A shares, using permitted trading methods on the Shanghai and Hong Kong stock exchanges over a 12‑month period starting 12 April 2025.
As of the latest announcement, Xiong has acquired 100,000 A shares via centralized bidding on the Shanghai Stock Exchange for about RMB3.84 million, representing 0.01% of the company’s total share capital. The share increase plan remains incomplete and subject to market conditions, signaling management’s confidence in the company while acknowledging that fluctuations in capital markets could hinder full execution of the planned purchases.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, focused on the research, development and commercialization of innovative biologic drugs. The company targets domestic and international markets with a portfolio centered on advanced therapies, positioning itself within the competitive biotech and pharmaceutical industry.
Average Trading Volume: 3,251,491
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.5B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.